HC Wainwright Reiterates “$5.00” Price Target for Veru (VERU)
VERU has been the subject of a number of other reports. Zacks Investment Research upgraded Veru from a hold rating to a buy rating and set a $2.50 price target for the company in a report on Wednesday, September 27th. ValuEngine cut Veru from a hold rating to a sell rating in a report on Friday, November 17th.
Veru (NASDAQ VERU) traded down $0.08 during midday trading on Wednesday, hitting $1.21. The stock had a trading volume of 71,555 shares, compared to its average volume of 165,977. The stock has a market cap of $64.38, a PE ratio of -5.26 and a beta of 1.24. Veru has a fifty-two week low of $0.90 and a fifty-two week high of $3.00.
COPYRIGHT VIOLATION NOTICE: This report was first posted by Marea Informative and is the property of of Marea Informative. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.mareainformativa.com/2018/01/29/hc-wainwright-analysts-give-veru-veru-a-5-00-price-target-updated-updated-updated.html.
Veru Company Profile
Veru Inc, formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.